Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent, Cell Line Genetics Collaborate

Published: Thursday, February 13, 2014
Last Updated: Thursday, February 13, 2014
Bookmark and Share
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.

Agilent Technologies Inc. announce a collaboration with Cell Line Genetics, Inc (CLG). CLG will develop high-throughput, genomic characterization workflows to confirm and monitor the integrity of cell lines for translational and regenerative medicine research. The workflows will be based upon Agilent’s custom, targeted CGH+SNP microarrays and SureFISH technology.

“Cell Line Genetics customers in the regenerative medicine research market include leading research institutions, biotechnology and pharmaceutical companies,” said Victor Fung, Agilent’s senior director of Global Marketing for the Genomics Solutions Division. “These diverse customers will benefit from services better tailored to meet their needs. In addition, Cell Line Genetics can better control operating costs because targeted array CGH designs can focus probe density where it matters most, enabling much faster data interpretation than SNP microarrays. Speed of analysis is particularly important in this high-throughput environment.

CLG selected Agilent’s genome-wide CGH+SNP microarrays for their capability, in a predictable high-throughput environment, to detect amplifications, deletions and cell line clonality with high sensitivity. CLG will use FISH assays to confirm aberrations identified down to the single-cell level. This approach provides a robust, best-in-class means of characterizing genome integrity and purity.

For cancer cell line characterization, CLG will offer array CGH (aCGH) services as it is able to simultaneously detect a large number of anomalies more accurately, with higher sensitivity, and with better coverage than traditional cytogenetics. In addition, when using aCGH, CLG can offer a faster turnaround time to customers.

After testing more than 15,000 stem cell lines, CLG found that 20 percent showed aneuploidy, and 60 to 70 percent of those were mosaic. Most significantly, the cells harboring genomic anomalies can have a proliferative advantage and overtake the culture, compromising the validity of study data and resulting in the loss of samples, time and funds.

“Collaborating with Agilent on custom microarray and SureFISH probe solutions gives us the most flexibility to innovate and expand our services,” said Rob Herrera, CEO and president, Cell Line Genetics. “For example, we can fortify our arrays in regions that we have identified as ‘integrity critical’ for even greater sensitivity. It allows us to easily design proprietary arrays and assays to support our customer’s research and translational needs.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies to Build New Facility in Colorado
Agilent buys 20 acres in Weld County to increase pharmaceutical manufacturing capacity.
Wednesday, August 10, 2016
Agilent, Eurofins Genomics Collaborate
Agilent plans to offer custom components and an assembled plasmid service for Agilent’s SureVector next-generation cloning kits through a collaboration with Eurofins.
Monday, March 14, 2016
Best Practices for Breast Cancer Diagnosis
Agilent has published “Breast Cancer Diagnosis: Past, Present and Future,” a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
Monday, March 14, 2016
Agilent Technologies Announces Early Access to Custom guideRNA for Functional Genomics
Company has announced a program that gives biologists conducting functional genomics research early access to a potential new resource.
Saturday, February 13, 2016
Agilent Technologies and 10x Genomics Announce Collaboration
Company has announced collaboration to develop a premium exome that provides a streamlined workflow for 10x Genomics'Chromium platform.
Friday, February 12, 2016
Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent Recognizes Australian Genome Research Facility as Certified Service Provider
Nonprofit organization offers scientists access to leading-edge technologies.
Saturday, October 31, 2015
Agilent Announces Opening of Life Science Research Center
Facility designed to advance multi-omics research.
Thursday, September 24, 2015
Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent’s Microarray Scanner Approved for In Vitro Diagnostics in China
Regulators approve SureScan Dx as medical device.
Wednesday, January 28, 2015
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent Announces Global Distribution Agreement with Cartagenia for CNV Analysis
To assist cytogenetic labs in the clinical interpretation of microarray data.
Friday, May 30, 2014
Agilent Thought Leader Award Supports Metabolic Research
Princeton team developing LC/MS methods, bioinformatics tools for discovery of metabolic regulatory mechanisms.
Tuesday, April 22, 2014
Agilent to Host Young Scientist Forums in Asia Pacific
Events provide platform for rising talents in Australia, Singapore to exchange ideas with leading scientific scholars.
Wednesday, March 26, 2014
Agilent Awards Grant for Translational Research in Cardiometabolic Disease
Dr. Christopher Newgard's team at Duke University use Agilent platforms to better understand disease mechanisms.
Thursday, January 16, 2014
Scientific News
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Modified Yeast Shows Plant Response to Key Hormone
Researchers have developed a toolkit based on modified yeast to determine plant responses to auxin.
Epigenetic Clock Predicts Life Expectancy
New research finds 5 percent of population ages faster, faces shorter lifespan.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!